# Cerebrolysin > A porcine-brain-derived mixture of neuropeptides and free amino acids with neurotrophic activity — approved for stroke and dementia outside the US. - Also known as: FPF-1070, porcine brain-derived peptide preparation - Class: Cognitive - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/cerebrolysin ## Overview Cerebrolysin is not a single molecule but a standardized mixture — low-molecular-weight neuropeptides (about 15%) and free amino acids (about 85%) produced by enzymatic breakdown of purified pig-brain proteins. Its small peptide fraction is able to cross the blood–brain barrier, where it is studied for mimicking the brain’s own neurotrophic factors. It is one of the most widely used injectable nootropics in the world, approved in dozens of countries for stroke, traumatic brain injury, and dementia — though not by the FDA. Cerebrolysin belongs to a small group of entries in this catalog that are not single peptides at all but defined biological mixtures — like the glycoprotein hormones, it cannot be captured by one molecular formula. It is manufactured by EVER Pharma (originally EBEWE, Austria) from purified porcine brain proteins broken down by controlled enzymatic hydrolysis, yielding a reproducible blend of short neuropeptides and free amino acids standardized by peptide-nitrogen content rather than by a sequence. The rationale is neurotrophic mimicry: the low-molecular-weight peptide fraction is small enough to cross the blood–brain barrier and is proposed to reproduce, in part, the actions of the brain’s own growth factors — BDNF, NGF, GDNF and others — that support neuron survival and synapse formation. It has one of the largest clinical literatures of any nootropic, spanning ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer’s disease, and is approved in roughly 44 countries across Europe and Asia. It is not FDA-approved in the United States, where it is imported and used off-label. ## Mechanism Neurotrophic and neuroprotective activity attributed to peptide fragments that mimic endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF), supporting neuronal survival, neuroplasticity, and synaptogenesis. ## Research areas Studied in: Stroke recovery, Traumatic brain injury, Vascular dementia, Alzheimer’s disease, Neuroprotection. Guides on this site: - [Cognition & Neuroprotection](https://americanpeptide.com/research-areas/cognition-neuroprotection): Nootropic and neurotrophic peptides studied for cognition and recovery. ## Key research - Neurotrophic mimicry — the peptide fraction is proposed to mimic endogenous neurotrophic factors (BDNF, NGF, GDNF), supporting neuronal survival and plasticity. - Stroke & TBI — the most-studied indications; used internationally in acute stroke and traumatic brain injury rehabilitation. - Dementia — studied and approved in several countries for vascular dementia and Alzheimer’s disease. - A defined mixture — not a single peptide but a standardized porcine-brain hydrolysate (≈15% peptides, ≈85% free amino acids); no single molecular formula. - Approved abroad, not by FDA — marketed in ~44 countries; not FDA-approved in the US. ## Storage, handling & synthesis **Synthesis.** Cerebrolysin is not synthesized but manufactured from purified porcine brain protein by controlled enzymatic hydrolysis, then standardized — its potency is defined by peptide-nitrogen content and a consistent low-molecular-weight profile, not by a single sequence or purity number. Because it is a biological mixture, quality rests on batch-to-batch reproducibility, species-source control, and freedom from larger proteins, closer to a biologic than to a synthetic peptide. ## FAQs ### What is Cerebrolysin? Cerebrolysin is a standardized mixture of small neuropeptides and free amino acids made from purified porcine brain proteins, studied for neurotrophic and neuroprotective effects in stroke, brain injury, and dementia. ### Is it a single peptide? No — it is a defined biological mixture (about 15% low-molecular-weight peptides and 85% free amino acids), so it has no single sequence or molecular formula. ### Is Cerebrolysin FDA-approved? No. It is approved in roughly 44 countries across Europe and Asia for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. This page is a research and educational reference. ### How is it thought to work? Its small peptides can cross the blood–brain barrier and are proposed to mimic the brain’s own neurotrophic factors (BDNF, NGF, GDNF), supporting neuron survival and synapse formation. ## Latest research Recent trials and publications mentioning Cerebrolysin, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy](https://clinicaltrials.gov/study/NCT06339411) — NOT_YET_RECRUITING · PHASE2 · NCT06339411 - [Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness](https://clinicaltrials.gov/study/NCT04427241) — RECRUITING · PHASE4 · NCT04427241 - [Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU](https://clinicaltrials.gov/study/NCT06052787) — COMPLETED · PHASE3 · NCT06052787 - [Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy](https://clinicaltrials.gov/study/NCT05821075) — RECRUITING · PHASE1, PHASE2 · NCT05821075 - [Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study](https://clinicaltrials.gov/study/NCT07043686) — RECRUITING · NA · NCT07043686 - [Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial](https://clinicaltrials.gov/study/NCT06899464) — NOT_YET_RECRUITING · PHASE4 · NCT06899464 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/cerebrolysin Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.